Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis
Tildrakizumab demonstrated effectiveness, with reduction from moderate-to-severe to mild disease and improved DLQI scores, without notable safety concerns, for up to 1 year in this real-world meta-analysis. Although real-world data must be interpreted cautiously because of heterogeneity and potential bias, these findings align with randomized trial results, further supporting the use of tildrakizumab in clinical practice.
Authors
- Aaron S. Farberg (ORCID: https://orcid.org/0000-0001-9572-8683)
- Kimberly Hofer (ORCID: https://orcid.org/0000-0002-0050-6541)
- Mir Sohail Fazeli (ORCID: https://orcid.org/0000-0002-0369-3848)
- Scott L. Gottlieb (ORCID: https://orcid.org/0000-0002-9455-3671)
- Victoria Barghout (ORCID: https://orcid.org/0000-0003-4234-1527)
- Otto LT Lam (ORCID: https://orcid.org/0000-0002-7973-3914)
- Neal Bhatia
- Thomas J. Ferro
- Jacob Mathew
Institutions
- Therapeutics Clinical Research (US)
- Schweiger Dermatology Group (United States) (US)
- Baylor Scott & White Health (US)
- Atlantic Health System (US)
- Sun Chemical (United States) (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1007/s13555-025-01625-6
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00